 |
|
Skeletal microdamage stable after first year
September 21, 2006Encouraging sign for long-term safety of bisphosphonates
Skeletal microdamage resulting from bisphosphonate treatment may be maximal during the first year of treatment, and not continue to accumulate with longer periods of treatment, according to new research being presented today at the 28th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR).
Bisphosphonates are the most common class of drugs used for the treatment of osteoporosis because of their demonstrated effect on fracture reduction but the incidence of microcracks-small cracks in the skeleton-has been shown to increase with bisphosphonate treatment. This has led to some concerns regarding the potential long-term adverse effects of these agents. This study shows that the continued use of alendronate (a bisphosphonate) is not associated with continued accumulation of microdamage.
Matt R. Allen, Ph.D., assistant research professor, and David B. Burr, Ph.D., chairman, both from the Indiana University School of Medicine Department of Anatomy and Cell Biology, Indianapolis, IN, evaluated the effects of alendronate in one-year-old female beagles. The beagles were given oral doses of alendronate at levels comparable to that employed in humans (.2 mg/kg/day) or at five times the clinical dose (1 mg/kg/day) for either 1 year or 3 years.
Researchers found there was no increase in vertebral microcracks after 3 years of alendronate treatment in comparison to the beagles treated for 1 year. These results suggest that microcrack accumulation is greatest during the early course of alendronate treatment. This is an encouraging sign for long-term safety of these drugs.
ASBMR President-Elect Steve Goldring, M.D., notes: "These findings have important clinical implications with respect to the long-term safety of bisphosphonates in patients with osteoporosis."
Indiana University
Matt R. Allen, Ph.D., assistant research professor, and David B. Burr, Ph.D., chairman, both from the Indiana University School of Medicine Department of Anatomy and Cell Biology, Indianapolis, IN, evaluated the effects of alendronate in one-year-old female beagles. The beagles were given oral doses of alendronate at levels comparable to that employed in humans (.2 mg/kg/day) or at five times the clinical dose (1 mg/kg/day) for either 1 year or 3 years.
Researchers found there was no increase in vertebral microcracks after 3 years of alendronate treatment in comparison to the beagles treated for 1 year. These results suggest that microcrack accumulation is greatest during the early course of alendronate treatment. This is an encouraging sign for long-term safety of these drugs.
ASBMR President-Elect Steve Goldring, M.D., notes: "These findings have important clinical implications with respect to the long-term safety of bisphosphonates in patients with osteoporosis."
Indiana University
Bisphosphonate Current Events and Bisphosphonate News RSSKilling Cancer Like a Vampire Slayer
Like vampires, cancer tumors require an ample supply of blood to stay alive. Without fresh blood for sustenance, cancer cells shrivel up like raisins and die.
Buyer beware: Estrogen supplements not as effective as claimed
Dietary supplements claiming to help postmenopausal women with bone health may not be doing what they say, according to new research from Purdue University.
Osteoporosis drug may save lives by strengthening immune system
An osteoporosis drug proven to save lives after hip fractures may do so by strengthening the body's immune system, according to geriatrics researchers at Duke University Medical Center.
Monitoring bone density in older women is unnecessary and potentially misleading
Monitoring bone mineral density in postmenopausal women taking osteoporosis drugs (bisphosphonates) is unnecessary and potentially misleading.
X-rays help predict permanent bone damage from bisphosphonates
Breast cancer patients, individuals at risk for osteoporosis and those undergoing certain types of bone cancer therapies often take drugs containing bisphosphonates.
Link between widely used osteoporosis drugs and heart problems probed
New research at Wake Forest University School of Medicine evaluated the link between a common class of drugs used to prevent bone fractures in osteoporosis patients and the development of irregular heartbeat.
New drug agent knocks out multiple enzymes in cancer pathway
A team of 24 researchers from the U.S., Europe, Taiwan and Japan and led by University of Illinois scientists has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.
Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.
Majority of osteoporosis patients not receiving calcium and vitamin D with treatment
New research published today at the annual meeting of the American Society for Bone and Mineral Research (ASBMR), Montréal, Canada, reveals that less than half (43%) of patients in Europe with osteoporosis are claiming to take both calcium and vitamin D supplementation with their osteoporosis treatment.
Bone drug could help prevent the spread of breast cancer
Maintaining bone density could be a key to decreasing the spread of cancer in women with locally advanced breast cancer, according to research at Washington University School of Medicine in St. Louis.
More Bisphosphonate Current Events and Bisphosphonate News Articles
 |
Oral & Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology, Prevention, and Treatment by Robert E. Marx (Author) Since it was first identified in 2003, bisphosphonate-induced osteonecrosis has come under growing scrutiny by medical and dental specialists alike because it affects cancer patients receiving intravenous bisphosphonate therapy and osteoporosis patients receiving oral bisphosphonate therapy and yet its presentation of exposed bone is limited to the jaws. Based on a clear understanding of the disease mechanism and documented outcomes of the relatively small number of cases treated to date, this timely book presents definitive treatment protocols for patients who present at each stage in its progression. Equally important, it offers a simple method for predicting risk as well as crucial recommendations for steps that can be taken to prevent the disease from developing when bisphosphonate... |
 |
Bisphosphonates in Medical Practice: Actions - Side Effects - Indications - Strategies by Reiner Bartl (Author), Bertha Frisch (Author), Emmo von Tresckow (Author), Christoph Bartl (Author) Clinical osteology is now an independent specialty which nevertheless encompasses all branches of medicine and effects each and every one of us: Bone is Every Body's Business. This book has been designed as an up to date manual to deal with the currently recognized indications for bisphosphonates, to outline situations and conditions for prevention of skeletal disorders, and to provide practical guidelines for treatment. It is intended for doctors who seek precise information on bisphosphonates in medical practice to enable them to treat patients with disorders of bone or better still to avoid their occurrence - as the age-old saying has it 'prevention is better than cure'! Significant advances have already been made in the first 6 years of the 'Bone and Joint Decade' of the new century,... |
 |
Bisphosphonates: Webster's Facts and Phrases by Icon Group (Author) Ever need a fact or quotation on bisphosphonates? Designed for speechwriters, journalists, writers, researchers, students, professors, teachers, historians, academics, scrapbookers, trivia buffs and word lovers, this is the largest book ever created for this single word. It represents a compilation from a variety of sources with a linguistic emphasis on anything relating to the term "bisphosphonates," including non-conventional usage and alternative meanings which capture ambiguities. The entries cover all parts of speech (noun, verb, adverb or adjective usage) as well as use in modern slang, pop culture, social sciences (linguistics, history, geography, economics, sociology, political science), business, computer science, literature, law, medicine, psychology, mathematics, chemistry,... |
|
Gale Encyclopedia of Cancer: Bisphosphonates by Ph.D. Margaret Alic (Author) The article is excerpted from Gale Encyclopedia of Cancer The resource students and researchers will turn to for reliable, up-to-date and clearly written information, the Gale Encyclopedia of Cancer is a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures. The Encyclopedia includes entries covering cancers, cancer drugs, treatments, side effects and diagnostic procedures. Entries typically include the following elements: Causes and Symptoms Definition Description Diagnosis Prevention Resources Risks Special Concerns And more An appendix provides complete contact information for cancer centers, national support groups, government agencies and research groups. Features include... | |
|
Women on long-term bisphosphonate Tx do not need a drug holiday, experts say.(Rheumatology): An article from: Internal Medicine News by Timothy F. Kirn (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on November 15, 2004. The length of the article is 673 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Women on long-term bisphosphonate Tx do not need a drug holiday, experts say.(Rheumatology) Author: Timothy F. Kirn Publication: Internal Medicine News (Magazine/Journal) Date: November 15, 2004 Publisher: International Medical News Group Volume: 37 Issue: 22 Page: 21(1) Distributed by Thomson... | |
 |
The 2009-2014 Outlook for Bisphosphonates in Greater China by Icon Group International (Author) This econometric study covers the latent demand outlook for bisphosphonates across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in Greater China. For each major city in question, the percent share the city is of the region and of Greater China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the... |
|
Alternative to Oral Bisphosphonates.(pamidronate)(Brief Article): An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on April 1, 2000. The length of the article is 607 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Alternative to Oral Bisphosphonates.(pamidronate)(Brief Article) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: April 1, 2000 Publisher: International Medical News Group Volume: 30 Issue: 7 Page: 26 Article Type: Brief Article Distributed by Thomson... | |
|
Inflammatory bowel disease increases bone fracture risk: bisphosphonates warranted.(Gastroenterology): An article from: Internal Medicine News by Nancy Walsh (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on September 1, 2003. The length of the article is 490 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Inflammatory bowel disease increases bone fracture risk: bisphosphonates warranted.(Gastroenterology) Author: Nancy Walsh Publication: Internal Medicine News (Magazine/Journal) Date: September 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 17 Page: 42(1) Distributed by Thomson... | |
|
After 1 year of steroid therapy, one in six women have fractures. (Without Bisphosphonate Therapy).: An article from: Internal Medicine News by Nancy Walsh (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on March 1, 2003. The length of the article is 790 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: After 1 year of steroid therapy, one in six women have fractures. (Without Bisphosphonate Therapy). Author: Nancy Walsh Publication: Internal Medicine News (Magazine/Journal) Date: March 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 5 Page: 13(1) Distributed by Thomson... | |
|
Good dental hygiene and caution are urged to help prevent bisphosphonate-related jaw disease.(CARDIOVASCULAR HEALTH): An article from: Focus on Healthy Aging by Unavailable (Author) This digital document is an article from Focus on Healthy Aging, published by Belvoir Media Group, LLC on May 1, 2009. The length of the article is 552 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Good dental hygiene and caution are urged to help prevent bisphosphonate-related jaw disease.(CARDIOVASCULAR HEALTH) Author: Unavailable Publication: Focus on Healthy Aging (Magazine/Journal) Date: May 1, 2009 Publisher: Belvoir Media Group, LLC Volume: 12 Issue: 5 Page: 1(2) Distributed by Gale, a part of Cengage... |
| © 2009 BrightSurf.com |